RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection

Éric Lewitus, Eric Sanders‐Buell, Meera Bose, Anne Marie O’Sullivan, Kultida Poltavee, Yifan Li, Hongjun Bai, Thembi Mdluli, Gina Donofrio, Bonnie M. Slike, Hong Zhao, Kim Wong, Lennie Chen, Shana Miller, Jenica Lee, Bahar Ahani, Steven Lepore, Sevan Muhammad, Rebecca Grande, Ursula Tran, Vincent Dussupt, Letzibeth Mendez-Rivera, Sorachai Nitayaphan, Jaranit Kaewkungwal, Punnee Pitisuttithum, Supachai Rerks‐Ngarm, Robert J. O’Connell, Holly Janes, Peter B. Gilbert, Robert Gramzinski, Sandhya Vasan, Merlin L. Robb, Nelson L. Michael, Shelly J. Krebs, Joshua T. Herbeck, Paul T. Edlefsen, James I. Mullins, Jérôme H. Kim, Sodsai Tovanabutra, Morgane RollandVirus 2021 · DOI

TL;DR

This study investigated how the RV144 HIV-1 vaccine influenced the evolution of the virus after breakthrough infections. They found that specific "sieve signature" sites in the HIV-1 envelope gene, which were previously shown to differentiate vaccinees from placebo recipients, remained stable over time. Crucially, the virus evolved with less diversifying selection in vaccinated individuals, suggesting the vaccine imposed a constraint on viral evolution.

What Problem Does This Paper Address?

The HIV-1 epidemic remains a major global health challenge, and the development of an effective vaccine is a critical goal. However, HIV-1 is known for its high mutation rate and ability to rapidly evolve, raising concerns that it could adapt to and escape from a future vaccine once it's widely deployed. This rapid evolution, particularly within an infected individual (within-host evolution), could undermine vaccine efficacy. The RV144 trial was the first and only HIV-1 vaccine efficacy trial to show a reduction in infections, and it was associated with specific immune responses to the HIV-1 envelope (Env) protein, particularly the V1V2 region. Previous analyses of breakthrough infections in RV144 participants identified "sieve signature" sites in the Env gene that differed between vaccine and placebo groups, suggesting the vaccine exerted some selective pressure. This paper aims to understand if these vaccine-induced evolutionary pressures are sustained over time and how they impact the overall evolutionary trajectory of the virus post-infection.

Methods

The researchers analyzed HIV-1 env gene sequences collected from 110 participants in the RV144 trial who experienced breakthrough infections. These sequences were sampled at two time points: at diagnosis and approximately 6 months post-diagnosis.

Key methods included:

  • Sequence Alignment and Analysis: HIV-1 env sequences were aligned using MAFFT and checked for hypermutation.
  • Sieve Analysis: They focused on twelve "sieve signature" sites previously identified as distinguishing vaccine and placebo recipients. They analyzed the conservation of consensus amino acids at these sites over time and across groups.
  • Vaccine Response (VR) Score: A novel VR score was developed to quantify the degree of "escape" from vaccine pressure at the sieve signature sites. This score reflects how much an individual's viral sequences deviate from what would be expected if the vaccine were completely effective.
  • Estimates of Diversification: They used phylogenetic methods (spectral density profiles) and pairwise distance metrics to assess the overall diversification of viral populations within hosts.
  • Selection Analysis: Fixed effects likelihood methods were employed to identify sites under purifying (conserving) or diversifying (mutating) selection.
  • Analysis of Immune Pressure Sites: They examined mutations at known antibody (Ab) contact sites and predicted cytotoxic T lymphocyte (CTL) epitopes to assess the impact of different immune pressures.

Datasets

The primary dataset consisted of 2,635 HIV-1 env sequences from 110 participants in the RV144 vaccine efficacy trial. These sequences were collected at two time points: diagnosis and approximately 6 months post-diagnosis. For comparative analysis of site conservation, they also used a dataset of 521 independent circulating HIV-1 CRF01_AE sequences collected during a similar time period.

Key Insights and Ideas

  • Sieve Signatures Persist: The specific genetic "fingerprints" (sieve signatures) in the HIV-1 Env protein that were associated with vaccine protection at the time of infection remained stable in breakthrough viruses for at least six months. This suggests the vaccine's influence on viral evolution isn't just a transient effect at the moment of infection.
  • Vaccine Constrains Evolution: The most striking finding is that the virus evolved with significantly less diversifying selection in vaccinated individuals compared to placebo recipients. This implies the vaccine, even after breakthrough, continues to exert a selective pressure that limits the virus's ability to mutate and adapt freely.
  • Implications for Vaccine Roll-out: The study strongly suggests that if a partially effective HIV-1 vaccine were widely deployed, the virus might adapt by favoring strains that can escape vaccine-induced immunity. This could lead to the dominance of these vaccine-escaped variants over time.
  • Beyond Neutralization: The research highlights that vaccine-induced immune responses, even if not broadly neutralizing, can still impact viral evolution. The RV144 vaccine elicited binding antibodies that correlated with reduced infection risk, and these responses, rather than strong neutralizing or CTL responses, might be driving the observed evolutionary constraints.

Key Results

  • Sieve Signature Maintenance: Eleven out of twelve previously identified Env sieve signature sites were maintained over time (diagnosis to 6 months post-diagnosis) in breakthrough infections.
  • Lower Diversifying Selection in Vaccinees: At 6 months post-infection, vaccine recipients showed significantly fewer sites under diversifying selection in their viral env genes compared to placebo recipients (p=0.006).
  • Increased Diversifying Selection in Placebo: Diversifying selection increased over time in placebo recipients but not in vaccine recipients.
  • Vaccine Response (VR) Score: Per-participant VR scores were significantly higher in vaccine recipients than placebo recipients at both diagnosis and 6 months post-diagnosis, indicating that their viruses showed greater evidence of vaccine escape.
  • Neutralization Breadth: Vaccine recipients were less likely to develop broad neutralization breadth 3 years post-infection compared to placebo recipients. This lack of breadth was not directly associated with the number of potential escape mutations at Ab contact sites.

Limitations and Future Work

  • Unique Scenario: The study acknowledges that the RV144 trial represents a unique scenario of a vaccine with modest efficacy, making direct comparisons with other vaccine trials challenging.
  • HVTN 702 Trial: The authors note the HVTN 702 trial, a follow-up to RV144, showed a lack of efficacy, and suggest that understanding the differences in vaccine design, adjuvant, and circulating strains is crucial.
  • Future Directions: The paper emphasizes the need for future HIV-1 vaccines to consider evolutionary dynamics. They propose that multi-pronged vaccine approaches, similar to combination therapies for drug resistance, might be necessary to mitigate the risk of vaccine resistance. Further research is needed to understand the precise mechanisms by which vaccine-induced immune responses constrain viral evolution and how this might be leveraged in future vaccine designs.

Summary updated

Abstract

The scale of the HIV-1 epidemic underscores the need for a vaccine. The multitude of circulating HIV-1 strains together with HIV-1's high evolvability hints that HIV-1 could adapt to a future vaccine. Here, we wanted to investigate the effect of vaccination on the evolution of the virus post-breakthrough infection. We analyzed 2,635 HIV-1 <i>env</i> sequences sampled up to a year post-diagnosis from 110 vaccine and placebo participants who became infected in the RV144 vaccine efficacy trial. We showed that the Env signature sites that were previously identified to distinguish vaccine and placebo participants were maintained over time. In addition, fewer sites were under diversifying selection in the vaccine group than in the placebo group. These results indicate that HIV-1 would possibly adapt to a vaccine upon its roll-out.
BibTeX
@inproceedings{lewitus2021rv,
  author = {Éric Lewitus and Eric Sanders‐Buell and Meera Bose and Anne Marie O’Sullivan and Kultida Poltavee and Yifan Li and Hongjun Bai and Thembi Mdluli and Gina Donofrio and Bonnie M. Slike and Hong Zhao and Kim Wong and Lennie Chen and Shana Miller and Jenica Lee and Bahar Ahani and Steven Lepore and Sevan Muhammad and Rebecca Grande and Ursula Tran and Vincent Dussupt and Letzibeth Mendez-Rivera and Sorachai Nitayaphan and Jaranit Kaewkungwal and Punnee Pitisuttithum and Supachai Rerks‐Ngarm and Robert J. O’Connell and Holly Janes and Peter B. Gilbert and Robert Gramzinski and Sandhya Vasan and Merlin L. Robb and Nelson L. Michael and Shelly J. Krebs and Joshua T. Herbeck and Paul T. Edlefsen and James I. Mullins and Jérôme H. Kim and Sodsai Tovanabutra and Morgane Rolland},
  title = {{RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection}},
  booktitle = {Virus},
  year = {2021},
  doi = {10.1093/ve/veab057},
}
Figure